Cyclerion Therapeutics (CYCN) Operating Leases (2019 - 2021)

Cyclerion Therapeutics' Operating Leases history runs 3 years deep, the most recent figure standing at $38.1 million for Q1 2021.

• In Q1 2021, Operating Leases fell 19.1% year-over-year to $38.1 million; the TTM figure through Mar 2021 stood at $38.1 million (down 19.1% YoY), while the FY2020 annual figure was $38.9 million, down 44.78% from the prior year.
• Operating Leases was $38.1 million for Q1 2021 at Cyclerion Therapeutics, down from $38.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $72.4 million in Q2 2019 to a low of $38.1 million in Q1 2021.
• Historically, Operating Leases has averaged $53.1 million across 3 years, with a median of $46.7 million in 2020.
• The sharpest annual moves came in 2020 and 2021: Operating Leases tumbled 44.78% in 2020, then retreated 19.1% in 2021.
• A 3-year view of Operating Leases shows it stood at $70.5 million in 2019, then sank by 44.78% to $38.9 million in 2020, then fell by 2.22% to $38.1 million in 2021.
• The last three Operating Leases figures came in at $38.1 million (Q1 2021), $38.9 million (Q4 2020), and $39.8 million (Q3 2020), per Business Quant data.